Literature DB >> 22950958

The position of endoscopic procedures in the treatment of obesity.

Davor Stimac1, Sanja Klobucar Majanovic.   

Abstract

Obesity is a worldwide health problem associated with substantial morbidity and cost. Lifestyle modification and pharmacotherapy for obesity have limited benefit. Bariatric surgery is effective but with substantial risks, considerable cost and limited patient applicability. Endoscopic approach to obesity has evolved as a result of an attempt to replicate some of the anatomical manipulations and the physiological effects of the traditional weight loss surgery in a minimally invasive manner. Endoscopic interventions performed entirely through the GI tract offer the potential for an ambulatory weight loss procedure that is more cost-effective compared with current surgical approaches. There are two main endoscopic weight loss modalities - restrictive and malabsorptive. Restrictive procedures act to decrease gastric volume by space-occupying prosthesis and/or by suturing or stapling devices that alter gastric anatomy while malabsorptive procedures tend to create malabsorption by preventing food contact with the duodenum and proximal jejunum. Restrictive endoscopic procedures include intragastric balloon treatment, endoluminal vertical gastroplasty, transoral gastroplasty (TOGA) and transoral endoscopic restrictive implant system (TERIS). The duodenojejunal bypass sleeve (DJBS) is a malabsorptive device that mimics such surgical procedure. Gastroduodenojejunal bypass sleeve is a combination of both procedures. Except for intragastric balloon all mentioned procedures are rather novel, tested on a small number of subjects and with limited knowledge on safety and long-term efficacy. Owing to evolving field of evidence-based medicine with demand for rigorous evaluation of the scientific evidence these therapies need to be carefully tested in a randomized controlled manner to determine their safety and efficacy in the short and long-term. This review is aimed to compare endoscopic bariatric interventions with each other and with other weight loss modalities including conventional treatment and surgical procedures.

Entities:  

Mesh:

Year:  2013        PMID: 22950958     DOI: 10.2174/1574884711308030011

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  3 in total

1.  Reply to the article Espinós JC, Turró R, Mata A, Cruz M, da Costa M, Villa V, Buchwald JN, Turró J. Early experience with the Incision less Operating Platform™ (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg. 2013;23:1375-83.

Authors:  Ramon Vilallonga; Jacques Himpens
Journal:  Obes Surg       Date:  2014-03       Impact factor: 4.129

2.  Morbid Obesity: treatment with Bioenterics Intragastric Balloon (BIB), psychological and nursing care: our experience.

Authors:  Luigi Sivero; Giuseppe Galloro; Simona Ruggiero; Donato Alessandro Telesca; Teresa Russo; Maurizio Amato; Immacolata Di Palma; Speranza Iovino; Bruno Amato; Stefania Sivero; Pietro Forestieri
Journal:  Open Med (Wars)       Date:  2016-11-19

3.  Small bowel necrosis as a consequence of spontaneous deflation and migration of an air-filled intragastric balloon - a potentially life-threatening complication.

Authors:  Robert Drozdowski; Mariusz Wyleżoł; Mariusz Frączek; Piotr Hevelke; Marcin Giaro; Paweł Sobański
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2013-10-11       Impact factor: 1.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.